Mefatinib Impurity 2

Name: Mefatinib Impurity 2 | 31374-18-2
Brand: US-CATO
SKU: S57C4X-29922_200_MG
Price: 19998.0 USD
Availability: InStock

Cat. No S57C4X-29922_200_MG

Vendor: US-CATO

Product Information

Product Name

Mefatinib Impurity 2

Brand Name

US-CATO

Product Number

C4X-29922

CAS

31374-18-2

Certificate of Analysis (COA)

COA not found

General Information

PubChem CID

135416175

IUPAC Name

7-chloro-3H-quinazolin-4-one

InChI Key

PMLONMIODRHERC-UHFFFAOYSA-N

SMILES

C1=CC2=C(C=C1Cl)N=CNC2=O

References

Molecular modeling aided design, synthesis and biological evaluation of quinazoline derivatives for the treatment of human cancer

Publication Name: Molecular Diversity

Publication Date: 2025-01-20

DOI: 10.1007/s11030-025-11111-y

Structure–Activity Relationship and Molecular Docking of Quinazolinones Inhibiting Expression of COX-2, IL-1β, iNOS, and TNF-α through NF-κB Pathways

Publication Name: ACS Medicinal Chemistry Letters

Publication Date: 2023-08-15

DOI: 10.1021/acsmedchemlett.3c00098

Synthesis, In Vitro Antiproliferative Activity, and In Silico Studies of New Anilinoquinazoline Derivatives as Potential AntitumorAgents

Publication Name: Russian Journal of General Chemistry

Publication Date: 2020-12

DOI: 10.1134/s1070363220120294

Quantification of [18F]afatinib using PET/CT in NSCLC patients: a feasibility study

Publication Name: EJNMMI Research

Publication Date: 2020-08-17

DOI: 10.1186/s13550-020-00684-4

Synthesis and SAR optimization of quinazolin-4(3H)-ones as poly(ADP-ribose)polymerase-1 inhibitors

Publication Name: European Journal of Medicinal Chemistry

Publication Date: 2012-04

DOI: 10.1016/j.ejmech.2012.02.001

Mefatinib Impurity 2

Product Information

General Information

References

Molecular modeling aided design, synthesis and biological evaluation of quinazoline derivatives for the treatment of human cancer

Structure–Activity Relationship and Molecular Docking of Quinazolinones Inhibiting Expression of COX-2, IL-1β, iNOS, and TNF-α through NF-κB Pathways

Synthesis, In Vitro Antiproliferative Activity, and In Silico Studies of New Anilinoquinazoline Derivatives as Potential AntitumorAgents

Quantification of [18F]afatinib using PET/CT in NSCLC patients: a feasibility study

Synthesis and SAR optimization of quinazolin-4(3H)-ones as poly(ADP-ribose)polymerase-1 inhibitors